Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2019 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio to Present at September 2019 Investor Conferences

NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
August 27, 2019 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
August 22, 2019 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine Designation to facilitate expedited development and review of MB-107 for XSCID NEW YORK...
August 13, 2019 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
August 12, 2019 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio to Present at 11th Annual Bioprocessing Summit

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
August 09, 2019 16:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
August 05, 2019 08:00 ET | Source: Mustang Bio, Inc.

FDA Clears IND for Mustang Bio’s MB-102 (CD123 CAR T)

NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
July 24, 2019 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia

NEW YORK, July 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
May 23, 2019 08:30 ET | Source: Mustang Bio, Inc.; St. Jude Children’s Research Hospital

Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019

NEW YORK, and MEMPHIS, Tenn., May 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
May 16, 2019 08:00 ET | Source: Mustang Bio, Inc.; Nationwide Children’s Hospital

Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma

NEW YORK and COLUMBUS, Ohio, May 16, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...